Patient`s Instructions for Use Albuterol Sulfate Inhalation Solution
... the drug may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, Albuterol ...
... the drug may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, Albuterol ...
Heroin and cocaine co-use in a group of injection drug users in
... Cohort eligibility criteria included being 14 years of age or older, residing in Montréal and having injected drugs within the past 6 months. Subjects were either self-referred or referred by treatment programs, shelters, needle-exchange programs or friends. Injection drug users who were admitted fo ...
... Cohort eligibility criteria included being 14 years of age or older, residing in Montréal and having injected drugs within the past 6 months. Subjects were either self-referred or referred by treatment programs, shelters, needle-exchange programs or friends. Injection drug users who were admitted fo ...
Practicalities in the Use of Obesity Pharmacologic Agents
... • If <3% weight loss after 12 wks, either discontinue or advance to full dose phentermine 15/ topiramate ER 92 (transition dose phentermine 11.25/ topiramate ER 69 for 2 wks) • If <5% weight loss after 12 wks on full dose, discontinue (take every other day for 1 wk) Phentermine and topiramate extend ...
... • If <3% weight loss after 12 wks, either discontinue or advance to full dose phentermine 15/ topiramate ER 92 (transition dose phentermine 11.25/ topiramate ER 69 for 2 wks) • If <5% weight loss after 12 wks on full dose, discontinue (take every other day for 1 wk) Phentermine and topiramate extend ...
PRODUCT MONOGRAPH Pr PERIDEX ORAL RINSE
... Peridex (0.12% chlorhexidine gluconate) therapy should be initiated directly following a dental prophylaxis. Patients using Peridex should be reevaluated and given a thorough prophylaxis at intervals no longer than six months; they should be referred for periodontal consultation as necessary. Recomm ...
... Peridex (0.12% chlorhexidine gluconate) therapy should be initiated directly following a dental prophylaxis. Patients using Peridex should be reevaluated and given a thorough prophylaxis at intervals no longer than six months; they should be referred for periodontal consultation as necessary. Recomm ...
Mycobacterium tuberculosis from Tshwane Metropolitan OLUWASEGUN OLAYINKA ATANDA
... agar-based media have provided the most comprehensive published evidence and regarded as the reference methods in many countries (CLSI). These methods are based on the estimation of growth or not of a Mycobacterium tuberculosis strain in the presence of a single ‘critical concentration’ of one drug. ...
... agar-based media have provided the most comprehensive published evidence and regarded as the reference methods in many countries (CLSI). These methods are based on the estimation of growth or not of a Mycobacterium tuberculosis strain in the presence of a single ‘critical concentration’ of one drug. ...
PANTOPRAZOLE SODIUM DELAYED-RELEASE
... Pantoprazole is metabolized mainly by CYP2C19 and to minor extents by CYPs 3A4, 2D6 and 2C9. In in vivo drug-drug interaction studies with CYP2C19 substrates (diazepam [also a CYP3A4 substrate] and phenytoin [also a CYP3A4 inducer]), nifedipine, midazolam, and clarithromycin (CYP3A4 substrates), met ...
... Pantoprazole is metabolized mainly by CYP2C19 and to minor extents by CYPs 3A4, 2D6 and 2C9. In in vivo drug-drug interaction studies with CYP2C19 substrates (diazepam [also a CYP3A4 substrate] and phenytoin [also a CYP3A4 inducer]), nifedipine, midazolam, and clarithromycin (CYP3A4 substrates), met ...
Non-steroidal anti-inflammatory drugs (NSAIDs)
... The aim of analysis was to establish whether there was a need for the development of an education package for physiotherapists, and if so, which areas this package would need to address. ...
... The aim of analysis was to establish whether there was a need for the development of an education package for physiotherapists, and if so, which areas this package would need to address. ...
- Boehringer Ingelheim (Canada)
... narrow-angle glaucoma or urinary retention. Worsening of Narrow-Angle Glaucoma: ATROVENT HFA should be used with caution in patients with narrow-angle glaucoma. Care should be taken to avoid spraying the mist into the eyes. Since the pressurized inhalation solution is applied via mouth piece and man ...
... narrow-angle glaucoma or urinary retention. Worsening of Narrow-Angle Glaucoma: ATROVENT HFA should be used with caution in patients with narrow-angle glaucoma. Care should be taken to avoid spraying the mist into the eyes. Since the pressurized inhalation solution is applied via mouth piece and man ...
Consumption of antibacterial agents
... Antibacterial agents are among the most frequently used drugs worldwide, and contribute immensely to human and animal health. However, the consumption of antibacterial agents is closely linked to emergence and spread of resistance in commensal and pathogenic species (1, 2). A high prevalence of resi ...
... Antibacterial agents are among the most frequently used drugs worldwide, and contribute immensely to human and animal health. However, the consumption of antibacterial agents is closely linked to emergence and spread of resistance in commensal and pathogenic species (1, 2). A high prevalence of resi ...
Rapanofal Package Insert
... immediately available. The clinical use of propofol without available supplemental oxygen and artificial ventilation has not been adequately evaluated and is not recommended. 3. Anesthesia effects: Careful monitoring of the patient is necessary when using Rapanofal™ injection as a maintenance anesthe ...
... immediately available. The clinical use of propofol without available supplemental oxygen and artificial ventilation has not been adequately evaluated and is not recommended. 3. Anesthesia effects: Careful monitoring of the patient is necessary when using Rapanofal™ injection as a maintenance anesthe ...
Synthesis of Clinical-Grade [18F]-Fluoroestradiol as a Surrogate
... clinical-grade [18 F]FES presents many challenging laboratory requirements. Yield and product quality may vary from one site to other. In-vivo target interaction studies of experimental drug in human by PET (using a surrogate tracer) can reduce the substantial uncertainty in early-phase drug develop ...
... clinical-grade [18 F]FES presents many challenging laboratory requirements. Yield and product quality may vary from one site to other. In-vivo target interaction studies of experimental drug in human by PET (using a surrogate tracer) can reduce the substantial uncertainty in early-phase drug develop ...
2.7.3 Emulgent-free nanoporous/nanoparticulate
... The excipient was used at 2, 5 and 10% w/w concentrations and two types of mixing approaches were used: premixing followed by further mixing in a manually operated mortar (PM) and a high speed elliptical-rotor-type mixer (Theta-Composer®, TC). Respirable fractions (obtained with a twin impinger app ...
... The excipient was used at 2, 5 and 10% w/w concentrations and two types of mixing approaches were used: premixing followed by further mixing in a manually operated mortar (PM) and a high speed elliptical-rotor-type mixer (Theta-Composer®, TC). Respirable fractions (obtained with a twin impinger app ...
Valproic acid metabolism and its effects
... young children may be at higher risk because of immature hepatic function and, most probably, because of a recognized (or undiagnosed) metabolic abnormality that could trigger the hepatic failure. However, adults with VPA-associated fatal hepatotoxicity (17–62 years) have also been reported (König ...
... young children may be at higher risk because of immature hepatic function and, most probably, because of a recognized (or undiagnosed) metabolic abnormality that could trigger the hepatic failure. However, adults with VPA-associated fatal hepatotoxicity (17–62 years) have also been reported (König ...
Prescribing Information
... (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established. ...
... (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established. ...
Ritalin LA
... Renal Insufficiency: Ritalin LA has not been studied in renally-impaired patients. Renal insufficiency is expected to have minimal effect on the pharmacokinetics of methylphenidate since less than 1% of a radiolabeled dose is excreted in the urine as unchanged compound, and the major metabolite (rit ...
... Renal Insufficiency: Ritalin LA has not been studied in renally-impaired patients. Renal insufficiency is expected to have minimal effect on the pharmacokinetics of methylphenidate since less than 1% of a radiolabeled dose is excreted in the urine as unchanged compound, and the major metabolite (rit ...
Dextroamphetamine Sulfate Extended
... that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of the hyperactive-impulsive or inattentive symptoms that caused impairm ...
... that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of the hyperactive-impulsive or inattentive symptoms that caused impairm ...
What is Methamphetamine? Pushback Fact Sheet
... Is Meth a Prescription Drug?2 Methamphetamine can be prescribed by a doctor to treat attention deficit hyperactivity disorder, narcolepsy, weight loss and other conditions, although it is rarely used medically, and only at doses much lower than those typically abused. It is classified as a Schedule ...
... Is Meth a Prescription Drug?2 Methamphetamine can be prescribed by a doctor to treat attention deficit hyperactivity disorder, narcolepsy, weight loss and other conditions, although it is rarely used medically, and only at doses much lower than those typically abused. It is classified as a Schedule ...
Elocom Cream, Ointment and Lotion Physicians` Prescribing
... considered. There may therefore be a very small risk of such effects in the human fetus. Like other topically applied glucocorticoids, Elocom should be used in pregnant women only if the potential benefit justifies the potential risk to the mother or the fetus. It is not known whether topical admini ...
... considered. There may therefore be a very small risk of such effects in the human fetus. Like other topically applied glucocorticoids, Elocom should be used in pregnant women only if the potential benefit justifies the potential risk to the mother or the fetus. It is not known whether topical admini ...
Antifungals and their use in veterinary ophthalmology - GEAC-UFV
... susceptibility vary considerably among fungal pathogens [27,28]. Initial treatment of patients with suspected fungal keratitis may be empiric, and choice of therapy is defined by previous clinical experience, available drugs, and financial constraints [14]. Because of risk of toxicity associated with ...
... susceptibility vary considerably among fungal pathogens [27,28]. Initial treatment of patients with suspected fungal keratitis may be empiric, and choice of therapy is defined by previous clinical experience, available drugs, and financial constraints [14]. Because of risk of toxicity associated with ...
Paresthesia (including formication) (postmarketing AE), reformating
... a naturalistic setting. Patients were randomized to fixed dose treatment groups receiving final doses of 10, 20, or 30mg/day of ADDERALL XR or placebo. ADDERALL XR or placebo was taken once daily in the morning for three weeks. Significant improvements in patient behavior, based upon teacher and par ...
... a naturalistic setting. Patients were randomized to fixed dose treatment groups receiving final doses of 10, 20, or 30mg/day of ADDERALL XR or placebo. ADDERALL XR or placebo was taken once daily in the morning for three weeks. Significant improvements in patient behavior, based upon teacher and par ...
Plavix - Sanofi Canada
... In patients with recent transient ischaemic attack (TIA) or stroke and who are at high risk of recurrent ischemic events, the combination of ASA and PLAVIX has not been shown to be more effective than PLAVIX alone, but the combination has been shown to increase major bleeding (see DRUG INTERACTIONS ...
... In patients with recent transient ischaemic attack (TIA) or stroke and who are at high risk of recurrent ischemic events, the combination of ASA and PLAVIX has not been shown to be more effective than PLAVIX alone, but the combination has been shown to increase major bleeding (see DRUG INTERACTIONS ...
Complaint Filed in US District Court, Midland
... and instructions to FDA staff, industry, and the public for obtaining information to help fulfill the Agency’s plans regarding the compounding of drugs for use in animals. The compliance policy guidance does not create or confer any rights for or on any person and does not operate to bind the Food a ...
... and instructions to FDA staff, industry, and the public for obtaining information to help fulfill the Agency’s plans regarding the compounding of drugs for use in animals. The compliance policy guidance does not create or confer any rights for or on any person and does not operate to bind the Food a ...
Manitoba Medications Return Program
... The Health Products Stewardship Association (HPSA) is a non-profit organization that is funded by leading suppliers in the health products industry to administer Medications Return Programs and Sharps Collection Programs throughout the country. As a Producer Responsibility Organization (PRO), the HP ...
... The Health Products Stewardship Association (HPSA) is a non-profit organization that is funded by leading suppliers in the health products industry to administer Medications Return Programs and Sharps Collection Programs throughout the country. As a Producer Responsibility Organization (PRO), the HP ...
Bad Pharma
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.